Shengmai Injection, a Traditional Chinese Patent Medicine, for Intradialytic Hypotension: A Systematic Review and Meta-Analysis
Table 1
Characteristics of included studies.
Include studies
Study Designs
Participants
Duration of dialysis
Cause of renal failure
Dialysis equipment
Modality of dialysis
Interventions
Outcomes
Date of study
First author
T/C
Age (mean or rang T/C) yrs
Gender M/F
CGN
CPN
ON
PRD
GN
DIN
HTN
O
Dialyser Dialysis membrane Dialysate
Experiment group
Control group
1999
Zhao
RCT
49
60/40*
21–65
28/21
0–5 yrs
40
2
3
4
Not mentioned
Not mentioned
SMI 40 mL + 5% glucose solution 200 mL ivgtt. 90–100 drops/min
0.9% Sodium Chloride solution 240 mL ivgtt. 90–100 drops/min
Clinical effect Scr Bun IDEM ECG Clinical symptom Adverse effect
2010
Liu
RCT
70
35/35
(53.96 ± 13.23)
42/28
6 months –5 yrs
Not mentioned
Not mentioned
Not mentioned
SMI 60 mL + 0.9% sodium chloride solution 250 mL ivgtt. + conventional therapy
Conventional therapy (change dialysate temperature, reduce or stop ultrafiltration, slow down blood flow, increase sodium concentration in dialysate, 50% glucose solution 250 mL ivgtt rapidly)
Clinical effect SBP DBP HR
2007
Zhou
RCT
14
70/70*
15–78 (42)
8/6
Not mentioned
Not mentioned
GambroAK90S Polysulfon Bicarbonate
4 h* 2-3/Week
SMI 60 mL + 0.9% sodium chloride solution 250 mL ivgtt.
50% glucose solution 60 mL + 0.9% sodium chloride solution 250 mL ivgtt.
Hypotension incidence
2009
Zheng
RCT
35
18/17 144/136*
(61.25)
22/13
>1 yrs
18
1
6
8
2
Fresenius4008S Polysulfon Bicarbonate
4 h* 3/Week
Shengmai injection 50 mL + 50% glucose 100 mL ivgtt. continuously during dialysis
50% glucose 100 mL ivgtt. continuously during dialysis
Hypotension incidence BP HR Clinical effect Adverse effect
2006
Jiang
RCT
18
200/152*
43–78 (61.2 ± 12.3)
10/8
33.5 ± 7.6 mo
10
2
2
1
3
Not mentioned
Not mentioned
30 min before dialysis: midodrine hydrochloride Tablet 5 mg po.; 1 h after dialysis: 5 mg po.; + SMI 60 mL ivgtt + conventional measures Once a day, 15 days for a course of treatment, lasting for 2-3 courses.
30 min before dialysis: midodrine hydrochloride Tablet 5 mg po.; 1 h after dialysis: 5 mg po. + conventional therapy (infusion of hypertonic liquid, or reduce the amount of ultrafiltration, or even stop dialysis.) Once a day, 15 days for a course of treatment, lasting for 2-3 courses.)
Clinical effect SBP DBP MAP HR Adverse effect
2009
Lv
RCT
32
16/16
(66.3)
18/14
>3 mo
9
10
12
1
GambroAK200 Cellulose acetate Bicarbonate
Not mentioned
SMI 60 mL + 0.9% sodium chloride solution 40 mL ivgtt.
0.9% Sodium Chloride solution 100 mL ivgtt.
MAP The number of nursing interventions.
2008
Wang
RCT
73
38/35
T: 60–72 C: 60–71
Not mentioned
Not mentioned
Not mentioned
Fresenius 4008B Cellulose acetate Bicarbonate
Not mentioned
SMI: no detailed information was provided.
Conventional therapy: no detailed information was provided.
Clinical effect The number of nursing interventions.
2009
Yu
RCT
36
100/80*
53.5
20/16
3 mo–3.5 yrs
Not mentioned
Fresenius 4008H/S Polysulfon Bicarbonate
4 h* 2-3/Week
SMI 60 mL + 0.9% sodium chloride solution 250 mL ivgtt. + conventional therapy
50% glucose solution 250 mL ivgtt + conventional therapy (reduce or stop ultrafiltration, slow down blood flow, increase sodium concentration in dialysate)
Hypotension incidence Clinical effect
2007
Cao
RCT
60
30/30
T: (62.1 ± 14.4) C: (60.0 ± 14.0)
Not mentioned
Not mentioned
Not mentioned
GambroAK200 Cellulose acetate Bicarbonate
Not mentioned
SMI: no detailed information was provided.
Conventional therapy: no detailed information was provided.
MAP The number of nursing interventions.
2001
Li
RCT
50
100/100*
18–75 (48.8)
32/18
Not mentioned
30
2
4
12
2
Gambro AK-10, AK-90, AK-200 Bicarbonate
Not mentioned
SMI 10–40 mL + 50% glucose solution 20–40 mL iv..
0.9% saline 300~500 mL, or 20% human albumin 50 mL, or fresh plasma 200~400 mL ivgtt.
